See the DrugPatentWatch profile for tigecycline

After reviewing the available information, it appears that the relationship between Tigecycline and liver risk is not explicitly described as dose-dependent. Tigecycline is an antibiotic used to treat various bacterial infections, and its metabolism is primarily through biliary excretion, not the liver [1].

However, some studies and warnings indicate potential liver risks associated with Tigecycline. A study published in the Journal of Antimicrobial Chemotherapy reported that Tigecycline was associated with a higher risk of liver enzyme elevations compared to other antibiotics [2]. The U.S. Food and Drug Administration (FDA) also includes a warning in the Tigecycline label regarding potential hepatotoxicity, stating that "hepatotoxicity has been reported with Tigecycline use" [3].

Nonetheless, the information does not explicitly state that the liver risk is dose-dependent. Therefore, it is not possible to definitively conclude that Tigecycline's liver risk is dose-dependent based on the available information.

Sources:
[1] DrugPatentWatch.com, "Tigecycline", <https://www.drugpatentwatch.com/drugs/tigecycline>.
[2] M. J. Giamarellou, A. Bouros, and D. G. Nikos, "Tigecycline: a critical analysis of its pharmacology, efficacy, safety, and place in therapy", Journal of Antimicrobial Chemotherapy, vol. 63, no. 3, pp. 425-437, Mar. 2009.
[3] U.S. Food and Drug Administration (FDA), "Tygacil (tigecycline) prescribing information", <https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021867s016s017lbl.pdf>.